NCT06124066View on ClinicalTrials.gov

THE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTS

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

September 30, 2022

Study Completion Date

October 30, 2022

Conditions
Ureteral StoneKidney StonesUreteral Stenosis
Interventions
DRUG

Mirabegron 50 MG

The participants were given mirabegron 50 mg or tamsulosin 0.4 mg and filled in the Ureteral Stent Symptom Questionnaire (USSQ), filled in directly when the patient arrived or by telephone.

Trial Locations (1)

90245

DR Wahidin Sudirohusodo Hospital, Hasanuddin University Hospital, and Akademis Jaury Jusuf Putra Hospital., Makassar

All Listed Sponsors
lead

Hasanuddin University

OTHER